Genmab

GMAB

Market cap $19.5B

Company Announcement COPENHAGEN, Denmark; December 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

Security selection in industrials and a notable overweight to the software industry within information technology were the key detractors from relative returns. Health care is among the three weakest performing sectors and is the portfolio's biggest relative detractor in relative returns YTD. Geographically, international markets have led domestic markets notably YTD, largely reflecting depressed valuations after a multiyear lag.

Media Release COPENHAGEN, Denmark; November 24, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the Citi Global Healthcare Conference in Miami at 9:45 AM EST ( 3 : 45 PM CE T ) on December 4 , 202 5 . A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations.

Genmab A/S (GMAB) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive VP & CFO Conference Call Participants Benjamin Jackson - Jefferies LLC, Research Division Presentation Benjamin Jackson Jefferies LLC, Research Division Good to see you all here. Welcome to day 3 of the Jefferies London Healthcare Conference.

Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

Media Release COPENHAGEN, Denmark; November 18, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have priced their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). The issue price of the Notes is 100.000%.

Company Announcement COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,059 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to standard of care R2.i In the study, treatment with fi.

COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to standard of care R2.i